Clinical trial
Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
NCT07162467 is registered in ClinicalTrials.gov with Tianjin Anding Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia.
- Lead sponsor
- Tianjin Anding Hospital
- Phase
- Observational
- Overall status
- Enrolling by invitation
- Start date
- February 19, 2024
- Completion date
- June 30, 2026
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.